Adlai Nortye (ANL) Retained Earnings (2022 - 2025)
Adlai Nortye (ANL) reported Retained Earnings of -$464.8 million for Q4 2025, down 8.28% year-over-year from -$506.8 million in Q4 2024, and down 3.84% on a QoQ basis from -$447.7 million in Q2 2025.
Adlai Nortye (ANL) has 4 years of Retained Earnings data on file, last reported at -$464.8 million in Q4 2025.
- Quarterly Retained Earnings fell 8.28% year-over-year to -$464.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$464.8 million (down 8.28% YoY) and the FY2025 annual result came in at -$464.8 million, down 8.28% from the prior year.
- Retained Earnings retreated to -$464.8 million in Q4 2025 per ANL's latest filing, from -$447.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $4.4 million in Q4 2023 and bottomed at -$464.8 million in Q4 2025.
- The 4-year median for Retained Earnings is -$417.2 million (2024), against an average of -$335.1 million.
- The widest annual swing landed in 2023, when Retained Earnings jumped 101.64%; it then sank 9857.23% in 2024.
- Tracing ANL's Retained Earnings over 4 years: stood at -$268.2 million in 2022, then surged by 101.64% to $4.4 million in 2023, then slumped by 9857.23% to -$429.3 million in 2024, then retreated by 8.28% to -$464.8 million in 2025.
- Per Business Quant, the three latest ANL Retained Earnings figures stand at -$464.8 million (Q4 2025), -$447.7 million (Q2 2025), and -$429.3 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 36.42 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 130.89 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | -464.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -464.85 Mn |
| Jun 30, 2025 | -447.65 Mn |
| Dec 31, 2024 | -429.32 Mn |
| Jun 30, 2024 | -405.06 Mn |
| Dec 31, 2023 | 4.40 Mn |
| Dec 31, 2022 | -268.22 Mn |